Phase 2 N=76 Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
Cervical Cancer
Primary: Tumor Response — 1; 7; 17; 34 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=12 Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
Effects of Immunotherapy · Metastatic/Recurrent Cervical Cancer · Cervical Adenocarcinoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 1; 0 Participants
Phase 3 N=12,167 Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
Cervical Cancer · Genital Warts
Primary: Incidence of the Composite Endpoint of Human Papillomavirus (HPV) 16/18-related Cervical Intraepithelial Neoplasia (CIN) 2 or Worse in the Base Study — 0.0; 0.4…
Phase 2 N=133 Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)
Cervical Intraepithelial Neoplasia · Cervical Dysplasia
Primary: Incidence of Objective Response — 32; 36; 30; 0 Participants — p=0.043
Phase 3 N=926 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Primary: Overall Survival Rate at 5 Years — 71; 72 Percentage of participants
Phase 3 N=515 Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix
Cancer of Cervix
Primary: Number of Participants With Progressive Disease or Death Due to Any Cause at 3 Years — 55; 83; 149; 141 participants — p=0.029
Phase 2 N=35 Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma
Uterine Cervical Cancer
Primary: Toxicity (Number of Participants With Serious Adverse Events) — 10 Participants
Phase 2 N=60 Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
Phase 3 N=5,759 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
Cervical Cancer · Genital Warts
Primary: Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer — 0; 1.2 incidence rate per 100…
Phase 2 N=18 CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer
Cervical Cancer · Endometrial Cancer · Ovarian Cancer
Primary: Number of Patients With Measurable Concentration of Gemcitabine in Uterine Vein (dFdC) — 5 Participants
Phase 2 N=41 Irinotecan Study For Cervical Cancer
Uterine Cervical Neoplasms
Primary: Response to Treatment Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Evaluable Population) — 8; 7; 11; 6 participant
N/A N=9 Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix
Cervix Carcinoma
Primary: Feasibility of Acquiring In-vivo High-Resolution Microendoscopy (HRME) Images of Cervix Prior to Conization
Phase 2 N=27 Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer
Cervical Cancer
Primary: Anti-tumor Activity as Measured by Surviving Progression-free — 59 percentage of participants
N/A N=467 HPV Test-and-Treat-Strategy Versus Cytology-based Strategy for Prevention of CIN2+ in HIV-Infected Women
HIV-1 Infection
Primary: Cumulative Rate of Cervical Intraepithelial Neoplasia (CIN2+) (CIN2, CIN3 or Invasive Cancer) by Week 130 — 24.9; 26.5 Events per 100 persons
Phase 1 N=15 Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer
HPV16 Associated Cervical Cancer
Primary: Safety and Feasibility as Assessed by Number of Participants With Treatment-related Adverse Events — 5; 3; 8; 7 Participants
Phase 2 N=38 Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer
Cervical Squamous Cell Carcinoma · Recurrent Cervical Carcinoma
Primary: Progression-free Survival Greater Than 6 Months — 30; 5 participants
Phase 2 N=18 HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma
HPV-Related Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) at 2 Years — 75.5 percentage of patients
Phase 3 N=608 Study of Cemiplimab in Adults With Cervical Cancer
Squamous Cell Carcinoma (SCC) · Recurrent or Metastatic, Platinum-refractory Cervical Cancer
Primary: Overall Survival (OS) — 11.7; 8.5 Months — p=<0.00001
Phase 2 N=130 Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
Cervical Carcinoma · Cervical Intraepithelial Neoplasia Grade 2/3 · Stage 0 Cervical Cancer
Primary: Histologic Regression — 40; 34.1 percentage of participants
Phase 3 N=364 Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer
Cervical Cancer
Primary: Overall Survival — 21.9; 19.5 months — p=0.125
Phase 2 N=23 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants
N/A N=329 Human Papillomavirus Infection and Virus Genotyping in Uterine Cervix Cancer in Venezuela
Cervical Cancer
Primary: HPV Identification — 95; 142; 78 biopsies
Phase 2 N=55 Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
Cervical Cancer
Primary: Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 1; 16 participants
Early Phase 1 N=13 Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia
Cervical Intraepithelial Neoplasia Grade 2/3 · Cervical Squamous Cell Carcinoma In Situ · Cervical Squamous Intraepithelial Neoplasia 2
Primary: Feasibility of Intravaginal Use 5-FU and Imiquimod on Alternating Weeks in Women With Biopsy Confirmed High Grade Cervical Squamous Intraepithelial Lesions. — 4; 1…
Phase 1 N=12 Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix
Cervical Cancer
Primary: Dose Limiting Toxicity(DLT)/Significant Dose Delay of Paclitaxel With Cisplatin as Assessed by CTC 2.0 After 6 Cycles of Treatment — 0; 0; 2; 2 participants
Phase 2 N=42 Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer
Cervical Adenocarcinoma · Cervical Squamous Cell Carcinoma · Human Papillomavirus Infection
Primary: Number of Adverse Events, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 — 56 Adverse Events
Phase 2 N=50 Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
Cervical Squamous Cell Carcinoma · Recurrent Cervical Cancer
Primary: Progression-free Survival Greater Than 6 Months — 23.9 percentage of participants
Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Phase 3 N=236 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
Cervical Cancer
Primary: Disease-free Survival (Percentage of Participants Alive Without Disease) — 86.4; 82.1; 76.2; 76.9 percentage of participants — p=0.56
Phase 2 N=6 The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer
Cervical Cancer
Primary: DLT Evaluation for Safety and Tolerability(Part A) — 0 participants